Paper
RSC Advances
(C]C), 1257, 1107 (C–O), 1028 (C–N), 811, 759, 418 cmꢁ1; H
NMR (300 MHz, DMSO-d6): dH 9.70 (s, 1H, OH), 7.35 (d, J ¼
8.82 Hz, 1H, H–Ar), 7.22–7.11 (m, 2H, H–Ar), 6.96 (d, J ¼ 8.05 Hz,
2H, H–Ar), 6.52–6.43 (m, 6H, H–Ar and NH), 5.57 (s, 1H, N–CH–
N), 3.70 (s, 3H, OCH3) ppm; 13C NMR (75 MHz, DMSO-d6): dC
160.6, 156.9 (C–O), 143.9, 134.8, 129.8, 127.2, 127.2, 120.0,
115.7, 112.9, 104.9, 101.5, 61.1 (N–C–N), 55.4 (OCH3) ppm.
2-(2,3-Dichlorophenyl)-2,3-dihydro-1H-perimidine (6l). FT-
IR (KBr) (nmax): 3348, 3235 (N–H), 3044 (C–H), 1625, 1600,
1493, 1420, 1403, 1382, 1265 (C]C), 1182, 1161, 1043 (C–N),
M. E. Abdel Rehim, Res. Chem. Intermed., 2012, 38, 1527–
1528.
1
5 (a) J. G. Lambardino and E. H. Wiseman, J. Med. Chem., 1974,
17, 1182–1188; (b) A. Puratchikody and M. Doble, Bioorg.
Med. Chem. Lett., 2007, 15, 1083–1090; (c) J. G. Lombardino
and E. H. Wiseman, J. Med. Chem., 1974, 17, 1182–1188; (d)
J. G. Lombardino, US Pat., 3772441, 1973; (e) T. Maier,
R. Schmierer, K. Bauer, H. Bieringer, H. Buerstell and
B. Sachse, US Pat., 4820335, 1989; (f) U. Ucucu, I. Iskdag
and B. Cakir, Gazi Univ. Eczacilik Fak. Derg., 1988, 5, 161–
165; (g) S. E. Wolkenberg, D. D. Wisnoski, W. H. Leister,
Y. Wang, Z. Zhao and C. W. Lindsley, Org. Lett., 2004, 6,
1453–1456.
1
835, 787, 757 (C–Cl), 603 cmꢁ1; H NMR (500 MHz, DMSO-d6):
dH 7.69 (d, J ¼ 8.15 Hz, 2H, H–Ar), 7.45 (t, J ¼ 7.90 Hz, 1H, H–Ar),
7.19 (t, J ¼ 7.78 Hz, 2H, H–Ar), 7.04 (d, J ¼ 8.15 Hz, 2H, H–Ar),
6.83 (s, 2H, NH), 6.52 (d, J ¼ 7.35 Hz, 2H, H–Ar), 7.83 (s, 1H, N–
CH–N) ppm; 13C NMR (125 MHz, DMSO-d6): dC 142.7, 141.8,
134.7, 132.1, 131.1, 130.7, 128.8, 128.6, 127.3, 116.1, 112.5,
105.0, 63.5 (N–CH–N) ppm.
6 K. V. Belyaeva, L. V. Andriyankova, L. P. Nikitina,
A. G. Mal'kina, A. V. Afonin and B. A. Tromov,
Tetrahedron Lett., 2012, 53, 7040–7043.
7 (a) T. A. Farghaly, M. A. Abdallah and Z. A. Muhammad, Res.
Chem. Intermed., 2015, 41, 3937–3947; (b) F. A. Bassyouni,
S. M. Abu-Bakr, K. H. Hegab, W. El-Eraky, A. A. E. Beih and
M. E. A. Rehim, Res. Chem. Intermed., 2012, 38, 1527–1550.
8 J. L. Davis, M. G. Papich and M. C. Heit, Antifungal and
Antiviral Drugs, in Veterinary Pharmacology and
Therapeutics, ed. J. E. Riviere and M. G. Papich, Wiley-
Blackwell, 9th edn, 2009, ch. 39, vol. 1019–1020, ISBN 978-
0-8138-2061-3.
2-(5-Nitrofuran-2-yl)-2,3-dihydro-1H-perimidine (6m). FT-IR
(KBr, nmax): 3434 (N–H), 1603, 1480 (C]C), 1520, 1360 (–NO2),
1
1020 (C–N), 808, 601 cmꢁ1; H NMR (300 MHz, DMSO-d6): dH
8.25 (d, J ¼ 7.00 Hz, 2H, H–Ar), 7.69 (s, 2H, H–Ar), 7.52–7.27 (m,
6H, H–Ar and 2NH), 5.25 (s, 1H, N–CH–N) ppm; 13C NMR (75
MHz, DMSO-d6): dC 161.3, 150.2, 137.0, 135.5, 130.1, 128.4,
124.4, 119.2, 116.1, 114.6, 69.7 (N–C–N) ppm.
9 (a) N. Xi, Q. Huang and L. Liu, in comprehensive heterocyclic
chemistry III, ed. A. R. Katritzky, C. A. Ramsden, E. F. V.
Scriven and R. J. K. Taylor, Elsevier science, Oxford, 2008,
vol 4, pp. 143–348; (b) L. De Luca, Curr. Med. Chem., 2006,
13, 1–23.
Conflicts of interest
There are no conicts to declare.
Acknowledgements
10 H. Debus, Ann. Chem. Pharm., 1858, 107, 199–208.
11 Z. Zarnegar and J. Safari, New J. Chem., 2014, 38, 4555–4565.
12 K. F. Shelke, S. B. Sapkal, S. S. Sonar, B. R. Madje,
B. B. Shingate and M. S. Shingare, Bull. Korean Chem. Soc.,
2009, 30, 1057–1060.
We are thankful to the Payame Noor University for the partial
support of this work.
13 S. D. Jadhave, N. D. Kokare and S. D. Jadhave, J. Heterocycl.
Chem., 2009, 45, 1461–1464.
References
1 L. Zhang, X. M. Peng, G. L. Damu, R. X. Geng and S. H. Zhou, 14 A. Shaabani, A. Rahmati, E. Farhangi and Z. Badri, Catal.
Med. Res. Rev., 2014, 34, 340–437. Commun., 2007, 8, 1149–1152.
2 (a) M. Zendehdel, A. Mobinikhaledi, H. Alikhani and 15 H. Weinmann, M. Harre, K. Koeing, E. Merten and
N. Jafari, J. Chin. Chem. Soc., 2010, 57, 683–689; (b) U. Tilestam, Tetrahedron Lett., 2002, 43, 593–595.
A. Mobinikhaledi, M. A. Bodaghi Fard, F. Sasani and 16 J. Liu, J. Chen, J. Zhao, Y. Zhao, L. Li and H. Zhang, Synthesis,
M. A. Amrollahi, Bulg. Chem. Commun., 2013, 45, 353–356.
2003, 2661–2666.
3 Y. L. Fan, X. H. Jin, Z. P. Huang, H. F. Yu, Z. G. Zeng, T. Gao 17 M. M. Khodaei, K. Bahrami and I. Kavianinia, J. Chin. Chem.
and L. S. Feng, Eur. J. Med. Chem., 201, 15, 347–365.
Soc., 2007, 54, 829–833.
4 (a) K. Undheim and C. Benneche, in Comprehensive 18 N. D. Kokare, J. N. Sangshetti and D. B. Shinde, Synthesis,
Heterocyclic Chemistry II, ed. A. R. Katritzky, C.W. Rees and 2007, 2829–2834.
E. F. Scriven, Pergamon, Oxford, 1996; (b) A. F. Pozharskii 19 (a) V. Paragamian, M. B. Baker, B. M. Puma and J. Reale, J.
and V. V. Dalnikovskaya, Russ. Chem. Rev., 1981, 50, 816–
835; (c) X. Bu, L. W. Deady, G. J. Finlay, B. C. Baguley and
W. A. Denny, J. Med. Chem., 2001, 44, 2004–2014; (d)
J. M. Herbert, P. D. Woodgate and W. A. Denny, J. Med.
Chem., 1987, 30, 2081–2086; (e) D. R. Luthin,
A. K. Rabinovich, D. R. Bhumralkar, K. L. Youngblood,
R. A. Bychowski, D. S. Dhanoa and J. M. May, Bioorg. Med.
Chem. Lett., 1999, 9, 765–770; (f) F. A. Bassyouni, S. M. Abu-
Bakr, K. H. Hegab, W. El-Eraky, A. A. El Beih and
Heterocycl. Chem., 1968, 5, 591–597; (b) A. Shaabani and
A. Maleki, Chem. Pharm. Bull., 2008, 56, 79–81; (c)
J. B. Hendrickson and M. S. Hussoin, J. Org. Chem., 1987,
52, 4137–4139; (d) J. J. Vanden Eynde, F. Delfosse,
A. Mayence and Y. V. Haverbeke, Tetrahedron, 1995, 51,
5813–5818; (e) I. Yavari, H. Mostafavi, D. Tahmassebi and
R. Hekmat-Shoar, Monatsh. Chem., 1997, 128, 675–679; (f)
V. A. Ozeryanskii, E. A. Filatova, V. I. Sorokin and
A. F. Pozharskii, Russ. Chem. Bull., 2001, 50, 846–853.
This journal is © The Royal Society of Chemistry 2019
RSC Adv., 2019, 9, 19333–19346 | 19345